儿童急性髓系白血病化疗后中性粒细胞减少持续时间长与预后较好相关
日本儿童白血病/淋巴瘤研究组AML-05研究显示,在未使用G-CSF并完成既定方案的患者中,化疗后中性粒细胞减少持续时间长与总生存率高(P=0·011)和复发率低(P=0·042)相关。提示化疗后骨髓抑制易感性可能与更好的AML治疗结局相关。
要点
- 未用G-CSF且完成方案者中,中性粒细胞减少时间长与总生存率高相关
- 中性粒细胞减少持续时间长与复发率低相关
- 结果支持个体化给药策略以改善AML疗效
核心结论
- 化疗后中性粒细胞减少持续时间长与儿童AML更好的治疗结局相关。
研究设计与样本
- 日本儿童白血病/淋巴瘤研究组AML-05研究,分析未使用G-CSF并完成既定治疗方案的儿童AML患者。
主要发现
- 中性粒细胞减少持续时间长与总生存率高相关(P=0·011)。
- 中性粒细胞减少持续时间长与复发频率低相关(P=0·042)。
临床怎么用
- 结果支持采用个体化药物剂量策略以改善AML患者的治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.
引用
- Aoki T, Takahashi H, Tanaka S, et al. Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. Br J Haematol. 2020. PMID: 32337716. doi:10.1111/bjh.16656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。